Form 4: Collegium Pharmaceutical Director John Freund Acquires Shares Through Restricted Stock Units

Director John Freund acquired 7,693 shares of Collegium Pharmaceutical through restricted stock units that vest on May 16, 2025.

Summary

• John Freund, a director at Collegium Pharmaceutical, acquired 7,693 shares of common stock on May 16, 2024, through the grant of restricted stock units (RSUs).
• These RSUs vest on May 16, 2025, contingent upon Freund's continued service as a director.
• Each RSU represents the right to receive one share of Collegium Pharmaceutical's common stock.
• Freund also indirectly owns 8,625 shares through Skyline Venture Management V, LLC and 34,788 shares through John Freund Family Partnership IV, L.P.
• Freund disclaims beneficial ownership of shares held by Skyline Venture Management V, LLC and John Freund Family Partnership IV, L.P. except to the extent of his proportionate pecuniary interest therein.
• Following the transaction, Freund directly owns 52,468 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction. The acquisition of shares by a director is generally viewed positively, but it's a routine event.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The RSUs will be settled on May 16, 2025, or earlier upon certain events such as the director's end of service, death, disability, or a change in control of the Issuer, in shares of the Issuer's common stock.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's acquisition of shares, which is a common occurrence.

Stakeholder Impact

• The acquisition of shares by a director could have a slightly positive impact on shareholder sentiment.

Key Dates